Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]
Irvine, CA — July 18, 2019 — ResearchDx will attend the Association of Molecular Pathology (AMP) in Baltimore, Maryland November 7–9, 2019. Please visit our booth #2967, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.
Irvine, CA — Oct 1, 2018 — ResearchDx will attend the Association of Molecular Pathology (AMP) in San Antonio, Texas, November 1–3, 2018. Please visit booth #602, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.
Irvine, CA — November 7, 2017 — ResearchDx will be at the Association for Molecular Pathology (AMP) in Salt Lake City, Utah, November 16-18, 2017. Please visit us at booth 608 or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.
Irvine, CA—October 2, 2017—ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and […]
Inside the heterogeneous tumor tissue samples sent to clinical pathology laboratories for HER2 gene testing are cancer genomes with their own inherent complexity. The biopsy (or surgical excision) tissue represents a mixture of genomes from the tumor and normal stroma. Further compounding the heterogeneity problem, tumor genomes harboring HER2 gene amplifications may have amplified HER2 […]
A web search for the term ‘genomic landscapes’ brings up a surprising number of publications from esteemed journals such as Cell, Science, and Nature Genetics. At first glance it would seem that the words ‘genomic’ and ‘landscape’ do not belong together. However, review of the many ‘genomic landscape’ publications from the past decade reveals a […]
Leading contract diagnostics organization has completed construction of a 12,000 square foot addition to their office in Irvine, CA creating a 30,000 square foot headquarters in Irvine, CA. ResearchDx, Inc. announced the completion of a major construction addition to their Orange County headquarters in Irvine California. The company’s building at 5 Mason in Irvine, CA […]
Say the words “HER2 gene amplification” and what immediately comes to mind is breast cancer. But did you know other cancers, including those of the stomach and esophagus (collectively called gastroesophagel adenocarinoma or GEA) can have too many (> 6) copies of the HER2 gene? That’s right, an estimated 20% of GEA cancers harbor an […]
Leading contract diagnostics organization demonstrates the value of DNA-based testing for identifying the HER2-Low genomic subtype in high-risk HER2 equivocal breast cancer Irvine, CA—December 1, 2016—ResearchDx/PacificDx announced today that it will share findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in breast cancer patients at this year’s San […]